[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking University Third Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":642},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,185,0,25,[9,44,81,103,124,146,170,195,221,246,273,295,317,344,367,396,420,448,471,496,526,546,576,597,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100651463","the-cohort-construction-project-of-peking-university-third-hospital-100651463",false,"NCT07761676","The Cohort Construction Project of Peking University Third Hospital","Inclusion Criteria:\n\n* Age ≥ 18 years. Participants must be from group health examination populations who have undergone at least two consecutive health examinations at our Physical Examination Center.\n\nExclusion Criteria:\n\n* Failure to provide informed consent. Incomplete data, including incomplete health examination self-administered questionnaires.","ALL","18 Years",{"count":19,"type":20},100000,"ESTIMATED","3 Years","OBSERVATIONAL","The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. The near-term goals emphasize the use of health check-up data combined with advanced artificial intelligence technologies to build disease prediction models and explore the association between retinal photographs and overall health status, which will assist in early screening and personalized interventions for high-risk populations. The medium- to long-term goals focus on biological age-related research, utilizing telomere length and multi-omics technologies to assess the differences between biological age and chronological age and analyze their key influencing factors. Data collection will be implemented through the health check-up centers of multiple campuses of PUTH.",[25,26],"Multiple Chronic Conditions (Unspecified)","Large-scale Health Examination Cohort",[28,29,30],"Health Management","Health Check-up","Cohort Study","RECRUITING","2026-08-09",{"date":34,"type":35},"2026-08-12","ACTUAL",{"date":37,"type":35},"2025-02-21",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Peking University Third Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":43},"100651415","68ga-sorb-petct-imaging-in-patients-with-solid-tumors-100651415","NCT07760012","68Ga-SorB PET\u002FCT Imaging in Patients With Solid Tumors","A Prospective, Single-Center, Open-Label Exploratory Study of 68Ga-SorB PET\u002FCT Imaging for the Diagnosis of Sortilin-Positive Solid Tumors","SORB-PET","Inclusion Criteria:\n\n* \\- Adults aged 18 to 75 years.\n* Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, or ovarian cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate hematologic, hepatic, renal, and coagulation function:\n* White blood cell count ≥ 4.0 × 10\\^9\u002FL or absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL;\n* Platelet count ≥ 100 × 10\\^9\u002FL;\n* Hemoglobin ≥ 90 g\u002FL;\n* PT or APTT ≤ 1.5 × upper limit of normal (ULN);\n* Total bilirubin ≤ 1.5 × ULN;\n* ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases);\n* ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases);\n* Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN.\n* Normal cardiac function.\n* Estimated life expectancy of at least 12 weeks.\n* Willing and able to comply with study procedures and follow-up.\n* At least one measurable target lesion according to RECIST version 1.1.\n* Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET\u002FCT imaging.\n* Clinically indicated to undergo 18F-FDG PET\u002FCT for tumor evaluation.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate.\n* Inability to tolerate PET\u002FCT imaging or complete study follow-up.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","75 Years",{"count":54,"type":20},50,"INTERVENTIONAL",[57],"NA","This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, or ovarian cancer will undergo 68Ga-SorB PET\u002FCT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET\u002FCT, using pathology results and\u002For clinical follow-up as the reference standard.\n\nThe primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET\u002FCT and 18F-FDG PET\u002FCT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.",[60,61,62,63,64,65],"Melanoma (Skin Cancer)","Hepatocellular Carcinoma","Lung Cancer","Breast Cancer","Pancreatic Cancer","Ovarian Cancer",[67,68,69,70,71,72,73,74],"Sortilin","68Ga-SorB","PET\u002FCT","Molecular Imaging","Diagnostic Imaging","Positron Emission Tomography","Radiotracer","Oncology",{"date":34,"type":35},{"date":77,"type":20},"2026-07-24",{"date":79,"type":20},"2028-12-31",{"name":41,"class":42},{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":55,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100650964","the-effect-of-ligament-of-marshall-excision-during-minimally-invasive-cardiac-surgery-coronary-artery-bypass-grafting-mics-cabg-on-the-prevention-of-postoperative-new-onset-atrial-fibrillation-a-multicenter-prospective-randomized-triple-blinded-study-100650964","NCT07755072","The Effect of Ligament of Marshall Excision During Minimally Invasive Cardiac Surgery-Coronary Artery Bypass Grafting (MICS-CABG) on the Prevention of Postoperative New-Onset Atrial Fibrillation: A Multicenter, Prospective, Randomized, Triple-Blinded Study","Inclusion Criteria:\n\n* Aged 18-80 years;\n* Coronary artery lesions meeting the indications for surgical revascularization, with planned MICS-CABG;\n* Signed an informed consent form agreeing to participate in the study;\n\nExclusion Criteria:\n\n* Patients with preoperative hemodynamic instability requiring emergency surgery;\n* History of paroxysmal or persistent atrial fibrillation prior to surgery;\n* Echocardiographic left atrial anteroposterior diameter (APD) ≥ 60 mm;\n* Patients with ejection fraction (EF) \\\u003C 40%, left ventricular diastolic dimension (LVDD) \\> 60 mm, left ventricular aneurysm, or severe arrhythmia who are at high risk of intraoperative hemodynamic instability;\n* Patients with concomitant mitral stenosis or regurgitation of moderate severity or greater;\n* Patients undergoing concurrent valve surgery or other intracardiac corrective procedures;\n* Patients with a history of renal insufficiency;\n* Patients receiving intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) circulatory support preoperatively;\n* Patients taking antiarrhythmic drugs other than beta-blockers prior to surgery, such as propafenone or amiodarone;\n* History of cardiac or thoracic surgery;\n* Poor pulmonary function, with a preoperative arterial blood gas analysis oxygen partial pressure (PaO₂) \\\u003C 60 mmHg at rest without oxygen supplementation;\n* Patients with a preoperative pacemaker implant;","80 Years",{"count":89,"type":20},628,[57],"After heart bypass surgery, many patients develop a heart rhythm problem called postoperative atrial fibrillation, or POAF for short. This issue happens to 20%-40% of all bypass patients. Even with smaller, less invasive surgical cuts or robot-assisted heart bypass operations, between 4.8% and 18.4% of people still get POAF.\n\nWhen POAF occurs, patients usually stay in the hospital longer and face higher medical bills. It also raises chances of serious complications like stroke, heart failure and heart attacks, and lowers long-term survival rates. Stopping POAF early is therefore key to helping patients recover better after surgery.\n\nPOAF comes from two main causes: personal health risks and stress from the surgery itself. Older age, high blood pressure, heart failure, lung disease, diabetes and overweight all make people more likely to develop irregular heart rhythms after an operation. Surgical trauma also plays a big role: cutting the breastbone, fluid building up around the heart, inflammation from heart-lung machines, pulling or stitching heart tissue, and unbalanced nerve signals during recovery can all spark POAF. Earlier studies have shown simple surgical adjustments can lower POAF risk safely, giving us a good basis to improve current surgery methods.\n\nThe Ligament of Marshall is a fibrous bundle-like structure left over from heart development before birth. Its special tissue structure makes it easy to trigger chaotic heart beats. It holds muscle tissue that creates looping abnormal electrical signals, plus nerve clusters that overactivate the body's stress response after surgery - this is a major cause of POAF. Doctors who fix irregular heart rhythms with catheter burns already target this ligament to stop repeat atrial fibrillation. Major heart surgery for long-term irregular heartbeats also routinely cuts this ligament without adding extra surgical risks.\n\nOur study will collect real clinical data to deepen the understanding of POAF and partial denervation therapy. Cutting the Ligament of Marshall during minimally invasive cardiac surgery-coronary artery bypass grafting (MICS-CABG) is an easy, low-risk step with no extra risk of collateral injury. We hope this method can lower the chance of irregular heartbeats after surgery, reduce the need for rhythm-control drugs and their side effects, and help patients maintain stable heart function and better daily life right after surgery.\n\nFor MICS-CABG, doctors do not need extra complicated steps to see and cut the Ligament of Marshall. We only make a small cut between the ribs on the left chest. After pericardial incision and suspension, this fibrous bundle-like structure is clearly visible and simple to operate on. Compared with traditional open-heart surgery that splits the whole breastbone, this small-cut approach avoids rough handling of the left heart and lessens overall surgical stress on patients.",[93],"Postoperative Atrial Fibrillation","NOT_YET_RECRUITING","2026-08-04",{"date":97,"type":35},"2026-08-10",{"date":99,"type":20},"2026-07-13",{"date":101,"type":20},"2028-01-31",{"name":41,"class":42},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":55,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100650141","unplanned-return-to-the-operating-room-in-orthopaedics-closed-loop-quality-improvement-programme-100650141","NCT07744633","Unplanned Return to the Operating Room in Orthopaedics: Closed-Loop Quality Improvement Programme","Effectiveness of a Hospital-Level Closed-Loop Management System for Unplanned Return to the Operating Room in Orthopaedics: A Multicentre, Prospective, Before-and-After Quality Improvement Study","UROR-LOOP","Inclusion Criteria:\n\n* A public secondary or tertiary general hospital or specialty hospital in China.\n* Has an independent orthopaedic ward and an established orthopaedic surgical team.\n* Has performed at least 2,000 orthopaedic surgical procedures per year during each of the previous three years.\n* Is willing to participate in the study and sign the study cooperation agreement.\n* The head of the orthopaedic department, or an authorized departmental representative, is willing to provide written informed consent on behalf of the participating department.\n* Has accessible hospital discharge records, surgical and anaesthesia information systems, and the information infrastructure required for data verification.\n* Is able to provide the required aggregated and de-identified study data and complete the scheduled follow-up assessments.\n\nExclusion Criteria:\n\n* Is currently conducting a similar quality improvement programme that may affect the evaluation of the study intervention.\n* Is unable to complete the required follow-up assessments or data reporting.\n* Experiences or is expected to experience major institutional restructuring during the study period that may substantially affect implementation of the intervention.\n\nThe unit of enrollment, intervention, and analysis is the participating hospital and its orthopaedic department. Individual patients are not recruited as research participants. Only aggregated and de-identified hospital-level data will be collected.",{"count":7,"type":20},[57],"This multicentre, prospective, before-and-after quality improvement study will evaluate a hospital-level closed-loop management programme for unplanned return to the operating room in orthopaedics. The unit of enrollment, intervention, and analysis is the participating hospital and its orthopaedic department. Approximately 20-30 secondary or tertiary public hospitals in China will be included. Individual patients will not be recruited as research participants, and only aggregated and de-identified hospital-level data will be collected.After baseline assessment and standardized training, participating orthopaedic departments will implement a closed-loop management programme comprising six core components: standardization of the definition of unplanned return to the operating room; establishment of a non-punitive reporting mechanism; appointment of a departmental coordinator; monthly case registration and multi-source data verification; regular department-wide case review and root-cause analysis; and development, implementation, and follow-up of continuous quality improvement actions.The primary outcomes include the underreporting rate or reporting accuracy and indicators of management quality, such as coordinator appointment, active reporting, case registration, data verification, case review, and completion of the closed-loop management process. Secondary outcomes include the rate of unplanned return to the operating room, common postoperative complications, mortality, unplanned readmission, length of hospital stay, and hospitalization costs. Intervention adherence will be assessed quarterly, and study outcomes will be evaluated every six months during the 36-month study period. The intervention will not alter patients' clinical treatment or require additional diagnostic or therapeutic procedures.",[115,116],"Unplanned Return to the Operating Room in Orthopaedics","Closed-Loop Quality Improvement Programme",{"date":118,"type":35},"2026-08-06",{"date":120,"type":20},"2026-09",{"date":122,"type":20},"2029-12",{"name":41,"class":42},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":130,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":55,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100649985","phase-2-mirvetuximab-soravtansine-combined-with-suvemcitug-in-platinum-resistant-recurrent-ovarian-cancer-100649985","NCT07741630","Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer","Inclusion Criteria:\n\n\\- Voluntary written informed consent signed prior to any study-related procedures.\n\nFemale age ≥ 18 years at the time of signing informed consent.\n\nHistologically confirmed high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer.\n\nDocumented platinum-resistant recurrence, defined as progression within 6 months after completion of the last platinum-based chemotherapy regimen (excluding primary platinum-refractory disease, defined as progression during or within 3 months of first-line platinum-based therapy).\n\nRadiologically confirmed disease progression during or following the most recent line of therapy.\n\nFRα-positive tumor status verified by the Ventana FOLR1 (FOLR-2.1) CDx IHC assay, defined as ≥25% of tumor cells showing ≥2+ membrane staining intensity.\n\nPresence of at least one measurable lesion according to RECIST v1.1 guidelines as evaluated by investigator imaging.\n\nMust have received 1 to 3 prior systemic antineoplastic therapy lines.\n\nMust have received prior treatment with bevacizumab.\n\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nAdequate washout period from prior antineoplastic therapy: ≥5 half-lives or ≥4 weeks for systemic therapy (whichever is shorter); ≥2 weeks for localized palliative radiotherapy.\n\nRecovery or stabilization of all toxicities from prior therapies to Grade ≤1 or baseline (NCI CTCAE v5.0).\n\nMajor surgery completed at least 4 weeks prior to initiation of study treatment, with postoperative toxicities recovered or stabilized.\n\nAdequate bone marrow, hepatic, and renal organ functions.\n\nExclusion Criteria:\n\n\\- Non-serous histological subtypes, including endometrioid, clear cell, mucinous, sarcomatous components, mixed histology containing any of these components, or low-grade\u002Fborderline ovarian tumors.\n\nPrimary platinum-refractory disease (failure to achieve CR\u002FPR to first-line platinum therapy or progression within 3 months after last platinum dose).\n\nPrior wide-field radiation therapy involving ≥20% of bone marrow.\n\nBaseline peripheral neuropathy \\> Grade 1 according to CTCAE v5.0.\n\nActive or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing medication\u002Fmonitoring (e.g., uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic macular edema, macular degeneration, papilledema, and\u002For monocular vision).\n\nHistory of multiple sclerosis, other demyelinating diseases, or Lambert-Eaton myasthenic syndrome.\n\nUncontrolled severe systemic comorbid conditions (e.g., active infection, non-infectious interstitial lung disease, or clinically significant cardiovascular\u002Fcerebrovascular events within 6 months prior to first dose) rendering the patient unsuitable for the study.\n\nHistory of hemorrhagic or ischemic stroke within 6 months prior to randomization\u002Fenrollment.\n\nHistory of hepatic cirrhosis (Child-Pugh Class B or C).\n\nHistory of bowel obstruction (including subileus) related to underlying disease within 6 months prior to study initiation.\n\nPresence of any of the following:\n\nHistory of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess;\n\nPelvic examination or CT scan indicating rectosigmoid\u002Fgastrointestinal involvement, or clinical signs\u002Fsymptoms of intestinal obstruction.\n\nNon-healing wounds, active ulcers, or bone fractures.\n\nHemoptysis (≥0.5 teaspoon \u002F \\~2.5 mL of fresh red blood per episode) within 4 weeks prior to first dose.\n\nHistory of Posterior Reversible Encephalopathy Syndrome (PRES).\n\nClinically significant proteinuria: Urine Protein\u002FCreatinine Ratio (UPC) ≥ 1.0 or dipstick protein ≥ 2+; if UPC ≥ 1.0 or dipstick ≥ 2+, 24-hour urine protein quantification must be ≤ 1.0 g\u002F24h to be eligible.\n\nHistory of pulmonary embolism.\n\nHistory of Grade 4 thromboembolic events.\n\nPrior treatment with mirvetuximab soravtansine, other FRα-targeting agents, or suvemcitug.\n\nUntreated or symptomatic central nervous system (CNS) metastases.\n\nMalignancy within 3 years prior to enrollment, except for localized cancers treated with curative intent with negligible risk of metastasis or death (e.g., adequately treated basal cell\u002Fsquamous cell skin cancer or carcinoma in situ of the cervix\u002Fbreast).\n\nPregnant or breastfeeding females.\n\nKnown hypersensitivity to any of the study intervention drugs or excipients.\n\nAny other condition that, in the opinion of the investigator, makes the patient unsuitable for trial participation.","FEMALE",{"count":132,"type":20},20,[134],"PHASE2","his is an open-label, single-center, single-arm, prospective Phase II trial evaluating the efficacy and safety of Mirvetuximab Soravtansine (MIRV) combined with Suvemcitug (SV) in patients with folate receptor alpha (FRα)-positive, platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. A total of 20 eligible patients will receive MIRV (6 mg\u002Fkg AIBW IV Q3W) and Suvemcitug (1.5 mg\u002Fkg IV Q2W) until disease progression or intolerable toxicity. The primary endpoint is investigator-assessed Progression-Free Survival (PFS) per RECIST v1.1.",[137],"PROC","2026-07-29",{"date":140,"type":35},"2026-08-03",{"date":142,"type":20},"2026-08-15",{"date":144,"type":20},"2028-04-30",{"name":41,"class":42},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":16,"minAge":153,"maxAge":87,"enrollmentInfo":154,"targetDuration":4,"studyType":55,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":43},"100649971","comparison-of-postoperative-functional-outcomes-between-subvastus-and-medial-parapatellar-approach-in-total-knee-arthroplasty-100649971","NCT07742696","Comparison of Postoperative Functional Outcomes Between Subvastus and Medial Parapatellar Approach in Total Knee Arthroplasty","Comparison of Postoperative Functional Outcomes Between Subvastus and Medial Parapatellar Approach in Total Knee Arthroplasty: a Prospective Random Controlled Trial","Inclusion Criteria:\n\n* Patients aged 50 to 80 who are diagnosed with end-stage knee osteoarthritis that require unilateral primary total knee arthroplasty;\n* Patients who are determined by clinical and laboratory tests to have no absolute surgical contraindications;\n* Patients with good compliance, willing and able to undergo follow-up observations as required and sign the informed consent form;\n\nExclusion Criteria:\n\n* Patients with a history of surgery on the affected knee joint in the past;\n* Patients with neuromuscular diseases;\n* Patients scheduled for knee joint replacement revision surgery;\n* Patients with active knee joint infection or systemic infection;\n* Patients who receive primary joint replacement due to non-knee osteoarthritis, such as rheumatoid arthritis, tuberculous arthritis, traumatic arthritis, etc;\n* Patients with valgus or varus deformity of the knee joint greater than 15°;\n* Patients with knee flexion deformity greater than 15°;\n* Patients whose heart and lung functions are determined by clinical and laboratory tests to be unable to tolerate surgery;\n* Patients with mental disorders who are unable to cooperate with treatment;\n* Patients who is lactating or pregnant;\n* Patients who are unwilling to participate in this study and did not sign the informed consent form;\n* Patients with poor compliance and inability to cooperate in completing the follow-up observers at critical times;\n* For any reason, the researchers believe that the subject is unlikely to complete this study.","50 Years",{"count":155,"type":20},84,[57],"This study aims to compare the effects of the medial parapatellar approach (MP) and the subvastus approach (SV) on postoperative clinical function in total knee arthroplasty (TKA). A total of 84 patients, who visit the Joint Surgery Department of Peking University Third Hospital and are diagnosed with end-stage knee osteoarthritis and require unilateral, primary total knee arthroplasty, will be recruited. The patients will be randomly assigned to two groups, with 42 patients in each group. TKA will be performed using the MP and SV approaches respectively. Postoperative data such as quadriceps muscle strength, the time of first unassisted straight leg raise (SLR), joint range of motion (ROM), KSS score, WOMAC score, SF-12 score, VAS score, and shear wave elastography (SWE) of the medial thigh muscle will be collected. The patients will be followed up for 2 years postoperatively to compare the short-term and long-term clinical functional outcomes of the two surgical approaches.",[159],"Osteoarthritis (OA) of the Knee",[161,162,163],"medial parapatellar approach","subvastus approach","total knee arthroplasty",{"date":140,"type":35},{"date":166,"type":20},"2026-07-15",{"date":168,"type":20},"2029-07-15",{"name":41,"class":42},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},"100627803","multisensor-wireless-pressure-microcatheter-for-microvascular-function-assessment-in-anocainoca-patients-a-prospective-multicenter-single-group-target-value-study-100627803","NCT07453381","Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA\u002FINOCA Patients: A Prospective, Multicenter, Single-Group Target Value Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, gender not limited;\n2. Symptoms of angina pectoris, or objective evidence of myocardial ischemia (e.g., electrocardiogram, myocardial injury markers, etc.);\n3. Visual assessment of coronary angiography shows diameter stenosis \\\u003C 50% and FFR \\> 0.8 (or cRR \\> 0.89);\n4. Microvascular function assessment is planned;\n5. Agree to participate in this clinical study and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Acute myocardial infarction, PCI, CABG, or valvular surgery following angiography within the past 30 days;\n2. Severe valvular disease requiring surgical or interventional treatment;\n3. Chest pain with known non-ischemic causes (e.g., pericarditis, pulmonary hypertension, esophageal spasm);\n4. Contraindications to CMR (e.g., certain types of pacemakers or defibrillators, severe claustrophobia);\n5. Clear contraindications to adenosine and ATP use (e.g., second- or third-degree atrioventricular block, sick sinus syndrome, severe asthma, systolic blood pressure below 90 mmHg);\n6. Renal insufficiency (eGFR ≤ 45 mL\u002Fmin\u002F1.73 m2) or currently undergoing dialysis;\n7. Severe heart failure or LVEF ≤ 35%;\n8. Severe organ disease or life expectancy less than 2 years;\n9. Known to be participating in other drug or device clinical trials that have not yet met the primary endpoint;\n10. Other investigators deem the candidate unsuitable for this clinical trial.",{"count":177,"type":20},114,"This study aims to evaluate the sensitivity and specificity of a multi-sensor wireless pressure microcatheter for the diagnosis of CMD in patients with ANOCA\u002FINOCA, using quantitative myocardial perfusion imaging of cardiac magnetic resonance (CMR) as a reference.",[180],"Coronary Microvascular Dysfunction (CMD)",[182,183,184,185,186],"Pressure Microcatheter","Microvascular Function Assessment","Angina with Non-obstructive Coronary Arteries","Ischaemia with Non-obstructive Coronary Arteries","Coronary Microvascular Dysfunction",{"date":188,"type":35},"2026-07-30",{"date":190,"type":35},"2026-06-30",{"date":192,"type":20},"2026-12-31",{"name":41,"class":42},5,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":202,"sex":16,"minAge":17,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":55,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":43},"100647607","large-language-model-assistance-for-clinical-decision-making-among-rural-physicians-100647607","NCT07711600","Large Language Model Assistance for Clinical Decision-Making Among Rural Physicians","Effect of Large Language Model Assistance on Clinical Decision-Making Among Rural Physicians: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Currently engaged in clinical practice at a rural primary healthcare institution in northwestern China.\n* Has received formal medical education and holds a relevant diploma or degree.\n* Able to read and understand clinical case materials in Chinese.\n* Able to use a computer to complete the study tasks.\n* Willing to participate and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Previously involved in the development of the clinical case tasks, reference answers, or scoring rubric for this study.\n* Previously participated in pilot testing involving the same clinical case tasks or study procedures.",true,"65 Years",{"count":205,"type":20},240,[57],"This study will evaluate whether, relative to conventional information retrieval approaches, direct large language models (LLM) access and LLM use training can improve the overall clinical decision-making ability of rural physicians in low-resource grassroots healthcare settings.",[209],"Clinical Decision-making",[211,212,213],"Large Language Models","Clinical Decision Support","Rural Physicians","2026-07-14",{"date":216,"type":35},"2026-07-17",{"date":218,"type":20},"2026-07",{"date":120,"type":20},{"name":41,"class":42},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":55,"phases":230,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":245,"locationsCount":4},"100647153","phase-4-effect-of-secukinumab-on-cardiorenal-outcomes-in-patients-with-cardiorenal-metabolic-syndrome-and-atherosclerotic-cardiovascular-disease-100647153","NCT07704190","Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease","A Prospective, Randomized, Open-Label, Parallel-Controlled Study to Evaluate the Efficacy and Safety of Targeted Interleukin-17A (IL-17A) Inhibitor (Secukinumab) on Cardiovascular and Renal Endpoints in Patients With Cardiorenal Metabolic Syndrome Complicated With Atherosclerotic Cardiovascular Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years at screening.\n2. Meet at least one metabolic abnormality:\n\n   1. Body mass index ≥ 23 kg\u002Fm²;\n   2. Waist circumference ≥ 80 cm (female) or ≥ 90 cm (male);\n   3. Fasting glucose 100-124 mg\u002FdL (5.6-6.9 mmol\u002FL) or glycated hemoglobin (HbA1c) 5.7-6.4%;\n   4. Serum triglycerides ≥ 3.51 mmol\u002FL;\n   5. Documented hypertension, metabolic syndrome, or diabetes mellitus.\n3. Meet at least one diagnostic criterion for chronic kidney disease:\n\n   1. eGFR ≥15 and \\\u003C60 mL\u002Fmin\u002F1.73 m² (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] creatinine equation);\n   2. UACR ≥ 200 mg\u002Fg with eGFR ≥ 60 mL\u002Fmin\u002F1.73 m² and documented albuminuria.\n4. Have documented atherosclerotic cardiovascular disease (at least one):\n\n   1. Coronary heart disease: history of myocardial infarction, prior coronary revascularization, or ≥50% major epicardial coronary artery stenosis confirmed by cardiac catheterization or coronary coronary computed tomography angiography (CTA);\n   2. Cerebrovascular disease: prior atherosclerotic stroke, prior carotid revascularization, or ≥50% carotid artery stenosis confirmed by imaging;\n   3. Symptomatic peripheral artery disease.\n5. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Clinical evidence or suspected active infection judged by investigators.\n2. History of myocardial infarction, stroke, transient ischemic attack, or hospitalization for unstable angina within 60 days prior to randomization.\n3. Planned coronary, carotid, or peripheral artery revascularization at randomization.\n4. Major cardiac surgery, non-cardiac major surgery, or major endoscopy within 60 days before randomization, or planned major surgery during the study period.\n5. Current use of systemic immunosuppressive agents (glucocorticoids, small-molecule immunosuppressants, biologic DMARDs, anti-tumor drugs).\n6. Long-term intermittent hemodialysis or peritoneal dialysis.\n7. History or confirmed evidence of active tuberculosis.\n8. History of inflammatory bowel disease.\n9. Active malignancy or carcinoma in situ within the past 5 years.\n10. Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg).\n11. Chronic heart failure classified as New York Heart Association (NYHA) Class IV.\n12. History of bone marrow or solid organ transplantation, or planned organ transplantation during the study.\n13. Known or suspected allergy to secukinumab or related excipients.\n14. Pregnant, lactating females, or females of childbearing potential without adequate effective contraception.\n15. Absolute neutrophil count \\\u003C2 ×10⁹\u002FL or platelet count \\\u003C120 ×10⁹\u002FL, or alanine aminotransferase (ALT) \u002F aspartate aminotransferase (AST) \\>2.5 × upper limit of normal.\n16. HbA1c ≥10% (≥86 mmol\u002Fmol).\n17. Any disease condition that may endanger subject safety or impair protocol compliance per investigator judgment.\n18. Subjects with inadequate standard therapy judged by investigators.",{"count":229,"type":20},100,[231],"PHASE4","This is a prospective, randomized, open-label, parallel-controlled clinical trial to evaluate the efficacy and safety of targeted IL-17A inhibition with secukinumab on cardiovascular and renal endpoints in 100 patients with cardiorenal metabolic syndrome and atherosclerotic cardiovascular disease (ASCVD). Eligible subjects will be randomized 1:1 to receive either secukinumab 75 mg subcutaneous injection every 4 weeks for a total of 12 weeks plus standard guideline-directed medical therapy, or standard medical therapy alone. The primary endpoint is the time to first occurrence of 3-point major adverse cardiovascular events (MACE, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) over a 2-year follow-up period. Key indicators include estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) for renal outcome assessment.",[234,235,236,237,238,239,240,241],"Cardiorenal Metabolic Syndrome","Atherosclerotic Cardiovascular Disease","Chronic Kidney Disease","Coronary Artery Disease","Hypertension","Type 2 Diabetes Mellitus","Peripheral Arterial Disease","Carotid Artery Stenosis",{"date":166,"type":35},{"date":166,"type":20},{"date":79,"type":20},{"name":41,"class":42},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":16,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":55,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":271,"locationsCount":272},"100645679","cardiopulmonary-exercise-testing-based-high-intensity-interval-training-for-improving-heart-failure-with-preserved-ejection-fraction-100645679","NCT07693049","Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction","CPHIT-HFpEF","Inclusion Criteria:\n\n1. Men and women aged 35-70 years;\n2. Physical inactivity \u002F sedentary lifestyle defined as:\n\n   Sedentary behavior: average daily sitting time \\> 6 hours over the past 6 months; AND\u002FOR Insufficient physical activity: average weekly moderate-intensity physical activity \\\u003C 150 minutes or vigorous-intensity physical activity \\\u003C 75 minutes as assessed by the International Physical Activity Questionnaire (IPAQ);\n3. Patients with HFpEF at Stage 4 of CKM syndrome who have been clinically stable within the past month (New York Heart Association \\[NYHA\\] functional class II-III);\n4. Willingness to improve health status through appropriate exercise.\n\nExclusion Criteria:\n\n1. Presence of contraindications to cardiopulmonary exercise testing (CPET);\n2. Positive findings on the exercise electrocardiogram (ECG) during CPET;\n3. Diagnosis of psychiatric disorders;\n4. Presence of movement disorders or lower extremity exercise-related injuries within the past 6 months;\n5. Women who are pregnant, breastfeeding, or planning to become pregnant in the near future;\n6. Other conditions deemed unsuitable for participation in this study by the investigators;\n7. Refusal to sign the informed consent form.","35 Years","70 Years",{"count":256,"type":20},192,[57],"Cardiovascular-Kidney-Metabolic (CKM) Syndrome is a continuous clinical disease spectrum integrating cardiovascular, renal, and metabolic disorders. Heart failure with preserved ejection fraction (HFpEF) is considered Stage 4 of CKM syndrome, characterized primarily by impairment of cardiac structure and function. Numerous studies have confirmed that exercise intervention is effective in improving metabolic profiles and inflammatory status in Stages 0-3 of CKM syndrome (e.g., obesity, metabolic syndrome, hypertension, and diabetes), and significantly improves clinical outcomes. However, for Stage 4 CKM syndrome, especially in patients with HFpEF, conventional exercise prescription faces significant challenges in balancing safety and efficacy. Moreover, traditional \"one-size-fits-all\" exercise rehabilitation strategies have failed to significantly improve clinical outcomes due to the lack of individualized precision approaches.\n\nTo address this gap, this study proposes to adopt a multicenter, randomized, controlled design, enrolling patients with HFpEF at Stage 4 of CKM syndrome and randomly assigning them to either a personalized high-intensity interval training (HIIT) intervention group or a standard care control group. The \\*\\*primary endpoint\\*\\* of this study is the change in peak oxygen consumption (peak VO₂) from baseline after 24 weeks of intervention. In addition, a series of \\*\\*secondary endpoints\\*\\* have been established for comprehensive evaluation, including inflammatory biomarkers, cardiac structure and function, quality of life, and composite clinical events. These endpoints aim to comprehensively assess the intervention effects from the perspectives of cardiopulmonary function, metabolism and inflammation, quality of life, and clinical outcomes, as well as to explore the underlying mechanisms.\n\nThis study is expected to validate the beneficial effects of personalized exercise on peak VO₂ and various secondary endpoints in patients with Stage 4 CKM syndrome. It will not only provide high-level evidence-based support for exercise therapy in HFpEF but also deepen the understanding of the role of exercise intervention in the full-course management of CKM syndrome, offering key scientific support for the development of precision prevention and treatment strategies across all stages.",[260],"HFpEF - Heart Failure With Preserved Ejection Fraction",[262,263,264,265,266],"HFpEF","CPET","HIIT","Peak VO2","Exercise","2026-07-12",{"date":214,"type":35},{"date":218,"type":20},{"date":144,"type":20},{"name":41,"class":42},12,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":130,"minAge":17,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":55,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":294,"locationsCount":43},"100646782","effects-of-glp-1ras-on-fertility-outcomes-in-obese-women-with-pcos-100646782","NCT07687667","Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS","Effects of GLP-1 Receptor Agonists Combined With Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Obese Women With Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* Women with a wish to conceive;\n* Women with PCOS (Rotterdam criteria);\n* 28 kg\u002Fm2≤BMI\\\u003C35kg\u002Fm2;\n* Age: 18-40 years old\n\nExclusion Criteria:\n\n* Women with diseases unsuitable for pregnancy or any other contraindications to infertility treatment Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (\\>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine abnormalities that may affect assisted reproductive outcomes, untreated hydrosalpinx Male azoospermia, severe oligozoospermia and asthenospermia, or patients receiving donor sperm treatment Chromosomal abnormalities, patients planning preimplantation genetic testing (PGT) or donor oocyte treatment History of recurrent miscarriag Allergic to or contraindicated for GLP-1 class medications.","40 Years",{"count":282,"type":20},406,[57],"The goal of this clinical trial is to examine whether GLP1-RA and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.",[286,287,288],"Polycystic Ovary Syndrome (PCOS)","Obesity","Infertility, Female","2026-07-01",{"date":291,"type":35},"2026-07-07",{"date":218,"type":20},{"date":122,"type":20},{"name":41,"class":42},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":130,"minAge":17,"maxAge":280,"enrollmentInfo":302,"targetDuration":4,"studyType":55,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":43},"100512089","real-time-continuous-glucose-monitoring-system-in-t2dm-with-pregnacy-100512089","NCT05947916","Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy","Effect of Real Time Continuous Glucose Monitoring System on Management of Women With Type 2 Diabetes Mellitus During Pregnancy in a Multidisciplinary Comprehensive System","Inclusion Criteria:\n\n* A clear history of type 2 diabetes, or a history of type 2 diabetes diagnosed in early pregnancy\n* Singleton gestation at 4-26 weeks, with substandard glycemic control (i.e., fasting glucose \\> 5.3 mmol\u002FL, and or 1 hour postprandial glucose \\> 7.8 mmol\u002FL, and or 2 hours postprandial glucose \\> 6.7 mmol\u002FL) after lifestyle intervention ± basal insulin therapy, as assessed by the endocrinology department. Patients who need insulin regimen with basal plus meal or insulin pump regimen.\n* Patients are willing and committed to establish and follow up in the obstetrics and gynecology departments of Peking University Third Hospital, Haidian District Hospital and Yanqing District Hospital during pregnancy, and are willing to provide information on obstetric examination and perinatal medical records if they are transferred to the hospital for special reasons for follow-up or delivery.\n* Voluntarily participate in the study, examine and follow up according to this project and sign informed consent.\n* Able to pass the screening period Adherence evaluation\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, specific type of diabetes or gestational diabetes\n* Pregnancy with severe comorbidities or diabetic complications for which obstetrics does not recommend continuation of pregnancy, including but not limited to the following: proliferative retinopathy, chronic kidney disease (eGFR less than 60 mL\u002Fmin\u002F1.73± massive proteinuria), known coronary and cerebrovascular disease, autoimmune system disease and receiving exogenous glucocorticoids or immunosuppressive therapy.\n* Patients who have been hospitalized for psychiatric treatment within 6 months prior to enrollment or are still on psychiatric medications.\n* Patients who have received other interventional studies.",{"count":205,"type":20},[57],"The prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age is increasing rapidly, and low glucose compliance leads to an increased risk of adverse pregnancy outcomes for mothers and infants during pregnancy in women with T2DM. Real-time continuous glucose monitoring (CGM) is an important tool for glucose monitoring and patient education, as it can continuously record blood glucose throughout the day and provide real-time feedback on high and low blood glucose levels. This is a multicenter, open-label, randomized controlled clinical study to investigate the efficacy, safety, and maternal and infant pregnancy outcomes of using real-time CGM monitoring compared with conventional self-monitoring of blood glucose (SMBG) on the basis of multidisciplinary management in pregnant women with T2DM. One hundred and twenty pregnant women with T2DM in early pregnancy who were enrolled in intensive insulin therapy were randomly divided into the real-time CGM group and the conventional SMBG group. The real-time CGM intervention group wore real-time CGM for more than 50% of the pregnancy in addition to regular SMBG; the control group only performed regular SMBG. Both groups wore Medtronic iPro 2 for 3 days in early, mid and late pregnancy, and the time in the target range of blood glucose (TIR) was recorded in a blinded manner. Primary outcome: differences in TIR between the two groups of pregnant women in early, mid, and late pregnancy. Secondary outcomes included differences in glycated hemoglobin, hypoglycemia, insulin dose before delivery, pregnancy weight gain, and maternal and infant pregnancy outcomes.",[306,307,308,309,310],"Type2diabetes","Pregnancy Related","Continuous Glucose Monitoring","Time in Range","Pregnancy Outcome",{"date":312,"type":35},"2026-07-02",{"date":314,"type":35},"2024-01-30",{"date":192,"type":20},{"name":41,"class":42},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":202,"sex":16,"minAge":323,"maxAge":254,"enrollmentInfo":324,"targetDuration":4,"studyType":55,"phases":326,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":4},"100644720","high-frequency-short-course-extracorporeal-shock-wave-therapy-for-partial-rotator-cuff-tears-study-protocol-for-a-multicenter-randomized-controlled-trial-100644720","NCT07673055","High-frequency Short-course Extracorporeal Shock Wave Therapy for Partial Rotator Cuff Tears: Study Protocol for a Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Age 30-70 years, male or female\n* MRI- or high-resolution ultrasound-confirmed partial-thickness rotator cuff tear (predominantly supraspinatus) or small full-thickness tear without retraction or displacement\n* Shoulder pain duration ≥3 months with Visual Analog Scale (VAS) score ≥4 (0-10 scale)\n* Willing and able to provide written informed consent and comply with the study protocol\n\nExclusion Criteria:\n\n* Large or massive full-thickness rotator cuff tear, tear with Grade II retraction or greater, or presence of a greater tuberosity bone cyst\n* Severe muscle fatty infiltration (Goutallier grade ≥3) on MRI\n* Uncontrolled diabetes mellitus (HbA1c \\>7.5%), hypothyroidism, or heavy smoking (≥20 pack-years)\n* Received local injection therapy (e.g., corticosteroids, platelet-rich plasma) to the affected shoulder within 4 weeks prior to enrollment\n* Concurrent shoulder pathologies including glenohumeral osteoarthritis, adhesive capsulitis (frozen shoulder), or shoulder instability\n* Systemic diseases (e.g., rheumatoid arthritis), bleeding disorders, or coagulopathy\n* Pregnancy or lactation\n* Contraindications to ESWT (e.g., cardiac pacemaker, malignancy at treatment site)\n* Inability to complete treatment or follow-up schedule","30 Years",{"count":325,"type":20},300,[57],"This is a multicenter, randomized controlled clinical study exploring three different extracorporeal shock wave therapy (ESWT) regimens for patients with partial rotator cuff tears, a common cause of chronic shoulder pain and limited movement. Traditional ESWT uses a once-weekly treatment schedule over 7 weeks, which takes a long time and leads to low patient compliance. This study aims to test two new high-frequency, short-course ESWT protocols, compare their pain relief, shoulder function improvement, tendon healing effect, safety and treatment adherence with the conventional regimen, and finally establish a more efficient, patient-friendly standardized treatment plan for clinical use. A total of 300 eligible participants will be recruited from 10 top-tier hospitals across China and followed up for 12 months after treatment.",[329],"Partial Rotator Cuff Tears (PRCTs)",[331,332,333,334,335],"Partial rotator cuff tears","Extracorporeal shock wave therapy","High-frequency short-course therapy","Shoulder pain","Treatment adherence","2026-06-22",{"date":338,"type":35},"2026-06-29",{"date":340,"type":20},"2027-01-01",{"date":342,"type":20},"2030-01-01",{"name":41,"class":42},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":351,"targetDuration":353,"studyType":22,"phases":4,"briefSummary":354,"conditions":355,"keywords":359,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":43},"100643905","the-impact-of-preoperative-quantitative-flow-reserve-qfr-on-early-postoperative-radial-artery-graft-outcomes-in-coronary-artery-bypass-grafting-100643905","NCT07669987","The Impact of Preoperative Quantitative Flow Reserve (QFR) on Early Postoperative Radial Artery Graft Outcomes in Coronary Artery Bypass Grafting","QFR-RADIAL","Inclusion Criteria:\n\n* Patients aged 18 to 80 years.\n* Patients whose angina pectoris significantly affects daily life and work, and for whom conservative medical treatment is ineffective, requiring coronary artery bypass grafting (CABG).\n* Preoperative coronary angiography data are available for quantitative flow ratio (QFR) analysis.\n* Patients with severe stenosis, defined as greater than 70% stenosis, in the three main coronary artery branches, including the left anterior descending artery, circumflex artery, and right coronary artery, with or without left main coronary artery stenosis greater than 50%.\n\nExclusion Criteria:\n\n* Patients who cannot tolerate CABG due to comorbidities or complications.\n* Patients requiring urgent CABG or percutaneous coronary intervention (PCI).\n* Patients with significant congestive heart failure or hemodynamic instability.\n* Patients with a history of previous CABG or PCI within the past 6 months.\n* Patients who have experienced a stroke within the past 6 months.\n* Patients requiring concurrent cardiac procedures, such as valve surgery, maze surgery, radiofrequency ablation, or pacemaker implantation.\n* Patients with allergies to contrast agents or antiplatelet medications, or with contraindications to antiplatelet medications due to bleeding risks.\n* Patients with a significant history of bleeding, marked leukopenia, neutropenia, thrombocytopenia, anemia, or bleeding diathesis.\n* Patients currently participating in other prospective clinical studies.\n* Patients who are unwilling to participate in this study.",{"count":352,"type":20},110,"12 Months","The goal of this observational study is to learn about the long-term effects of Quantitative Flow Reserve (QFR) assessment in patients undergoing Coronary Artery Bypass Grafting (CABG). The main question it aims to answer is:\n\nDoes preoperative QFR measurement improve graft outcomes and reduce major adverse cardiac and cerebrovascular events (MACE) in patients undergoing CABG?\n\nParticipants who are scheduled for CABG and have undergone preoperative QFR assessment will be followed for one year post-surgery. They will provide data on graft patency and report any occurrences of MACE through regular follow-up visits and questionnaires about their health status.",[356,357,358],"Quantitative Flow Reserve","Minimally Invasive Coronary Surgery","Radial Artery",[356,360,358],"minimally invasive coronary surgery",{"date":362,"type":35},"2026-06-25",{"date":364,"type":35},"2023-01-01",{"date":192,"type":20},{"name":41,"class":42},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":130,"minAge":374,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":55,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100643215","zishen-yutai-pill-for-patients-with-recurrent-implantation-failure-100643215","NCT07641088","Zishen Yutai Pill for Patients With Recurrent Implantation Failure","Zishen Yutai Pill for Patients With Recurrent Implantation Failure: a Randomized, Double-blind, Parallel-group, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for recurrent implantation failure;\n2. Aged between 20-40 years old (inclusive) when oocytes were retrieved, and \\\u003C43 at enrollment;\n3. Have at least 1 good-quality embryo for transfer;\n4. Intend to undergo frozen-thawed embryo transfer;\n5. Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n1. Concomitant unresolved intrauterine lesions (e.g., intrauterine adhesions grade III-IV, endometrial polyps ≥1 cm, acute endometritis), endometriosis (ASRM stage ≥III), or adenomyosis (uterine volume ≥8 weeks of gestation) that affect embryo implantation;\n2. Intend to undergo FET after preimplantation genetic testing (PGT), including aneuploidy screening (PGT-A), monogenic disease testing (PGT-M), chromosomal structural rearrangement testing (PGT-SR);\n3. Thin endometrium (\\\u003C7 mm) before enrollment;\n4. Concomitant severe genital malformations or genital neoplasms;\n5. Contraindications to estrogen and progestogen (e.g., history of breast cancer);\n6. Presence of medical contraindications to assisted reproductive technology, including that either partner has a severe psychiatric disorder, acute genitourinary tract infection, sexually transmitted disease, serious deleterious habit (e.g., drug abuse), or teratogenic exposure to radiation, toxic agent or medication that still under effect; or genetic diseases specified in the Law of the People's Republic of China on Maternal and Infant Health Care for which childbearing and PGT are contraindicated; or severe somatic diseases incompatible with pregnancy; or chromosomal abnormalities;\n7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 × the upper limit of normal (ULN), or serum creatinine (Scr) \\> ULN;\n8. Presence of poorly controlled severe systemic diseases, including cardiovascular, digestive, endocrine, and autoimmune diseases (e.g., antiphospholipid syndrome, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis);\n9. Use of traditional Chinese medicines with similar functions and indications to ZYP within 1 month before screening that may affect treatment efficacy. Chinese patent medicines such as Tiaojing Cuyun Pills, Kuntai Capsules, Peikun Pills, Qilin Pills, Jinfeng Pills, Gushen Antai Pills, and Chinese herbal decoctions containing Cuscutae Semen, Dipsaci Radix, Taxilli Herba, and Asini Corii Colla with kidney-tonifying and spleen-strengthening effects;\n10. Allergy to any component of the study drugs;\n11. Participated in another interventional trials within 1 month prior to enrollment;\n12. Deemed unsuitable for this study by the investigator.","20 Years","43 Years",{"count":377,"type":20},878,[57],"The goal of this clinical trial is to evaluate the efficacy of Zishen Yutai Pill (ZYP) on pregnancy outcomes following embryo transfer and its safety in patients with recurrent implantation failure. The main question it aims to answer is whether ZYP can improve live birth rate in participant's frozen embryo transfer (FET) cycles.\n\nResearchers will compare ZYP to a placebo (a look-alike substance with similar characteristics to ZYP) to see if it works to improve pregnancy outcomes.\n\nParticipants will:\n\n1. Start to receive ZYP or placebo (5g per time, 3 times daily) within the first 5 days of their initial menstrual cycle, and will undergo FET in the following cycle. The medication will be taken without interruption till the day of pregnancy test (2 weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with a negative β-HCG result, the intervention will be stopped.\n2. Baseline visit will be conducted on days 2-4 of the participant's first menstrual cycle. Subsequent clinic visits will follow the standard protocol for FET cycle, as outlined below:\n\nVisit 1 (days 2-4 of the second menstrual cycle); Visit 2 (day of ovulation or day of endometrial transformation); Visit 3 (day of embryo transfer); Visit 4 (2 weeks after embryo transfer); Visit 5 (5 weeks after embryo transfer). Follow-up is scheduled at 10 weeks after embryo transfer (Visit 6) and after delivery (Visit 7), and these can be conducted remotely.",[381],"Recurrent Implantation Failure",[383,384,385,386,387],"traditional Chinese medicine","Zishen Yutai pill","recurrent implantation failure","frozen-thawed embryo transfer","randomized controlled trial","2026-06-10",{"date":390,"type":35},"2026-06-11",{"date":289,"type":20},{"date":393,"type":20},"2029-12-31",{"name":41,"class":42},13,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":55,"phases":405,"briefSummary":406,"conditions":407,"keywords":410,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":419,"locationsCount":43},"100643628","efficacy-evaluation-of-intelligent-rehabilitation-programs-based-on-ai-powered-digital-rehabilitation-system-for-subacromial-impingement-syndrome-100643628","NCT07638761","Efficacy Evaluation of Intelligent Rehabilitation Programs Based on AI-Powered Digital Rehabilitation System for Subacromial Impingement Syndrome","Inclusion Criteria:① Meet the diagnostic criteria for SIS (Subacromial Impingement Syndrome), i.e., 3 or more of the following 5 signs: tenderness on the anterior or lateral aspect of the acromion; positive Neer sign; positive Hawkins-Kennedy sign; positive painful arc test; positive external rotation resistance test;\n\n* MRI shows hyperintensity indicating subacromial bursitis;\n\n  * Aged 18-60 years;\n\n    * Conscious, able to understand and cooperate with rehabilitation training, and willing to accept regular follow-up; ⑤ No shoulder surgery within the past 1 year, no other shoulder joint-related diseases, and no need for surgical intervention; ⑥ Voluntarily sign the informed consent form and commit to participating in the entire study.\n\nExclusion Criteria:① Concurrent shoulder dislocation, fracture, shoulder arthritis, calcific tendinitis, or other shoulder joint diseases;\n\n* History of shoulder surgery or current injury is an old tear (course \\>6 months without standardized treatment);\n\n  * Suffering from severe cardiovascular or cerebrovascular diseases, diabetes, rheumatoid arthritis, osteoporosis, or other systemic diseases that may affect rehabilitation outcomes;\n\n    * Cognitive impairment that prevents normal participation in rehabilitation training, or other conditions judged by the physician as making the patient unsuitable for the trial;\n\n      ⑤ Participation in other rehabilitation intervention clinical trials within the past 1 month.","60 Years",{"count":404,"type":20},93,[57],"This non-randomized controlled trial will compare the efficacy of a conventional rehabilitation program versus an AI-based digital rehabilitation system in patients with subacromial impingement syndrome (SIS).",[408,409],"Articular","Range of Motion",[411,412,413],"Subacromial Impingement Syndrome","Artificial Intelligence","Digital Rehabilitation System","2026-06-09",{"date":388,"type":35},{"date":417,"type":20},"2026-10-14",{"date":417,"type":20},{"name":41,"class":42},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":427,"targetDuration":4,"studyType":55,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":43},"100642575","phase-2-ev--toripalimab-vs-gc-as-neoadjuvant-therapy-in-locally-advancedhigh-risk-mibc-100642575","NCT07647289","EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced\u002FHigh-Risk MIBC","A Phase II, Two-arm, Open-label, Multicenter, Randomized Controlled Clinical Study Evaluating the Safety and Efficacy of Enfortumab Vedotin Combined With Toripalimab Versus Gemcitabine Combined With Cisplatin in the Neoadjuvant Treatment of Patients With Locally Advanced\u002FHigh-risk Muscle-invasive Bladder Cancer","Inclusion Criteria:\n\n* Voluntarily agree to participate in the study and sign the informed consent form (ICF).\n* Age ≥ 18 and ≤ 80 years at the time of signing the ICF.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically confirmed muscle-invasive urothelial carcinoma of the bladder, with variant histology components comprising \\\u003C 50%.\n* Radiographically confirmed non-metastatic urothelial carcinoma (M0). Clinical stage must be locally advanced or possess high-risk features, including at least one of the following: clinical stage cT3-T4aNxM0, or definitive high-risk cT2 (e.g., accompanied by tumor-related hydronephrosis, lymphovascular invasion).\n* Participants must be evaluated as fit for and scheduled to undergo radical surgery, and clinically fit to tolerate cisplatin-based chemotherapy.\n* Able to provide tumor tissue samples (at least 5 unstained slides, or paraffin scrolls\u002Fblocks).\n* Expected life expectancy of at least 12 weeks.\n* Adequate organ function, defined by the following laboratory values (obtained without blood transfusion within 14 days or growth factor support within 7 days prior to testing): Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL; Platelet count (PLT) ≥ 100 × 10\\^9\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × Upper Limit of Normal (ULN); Total bilirubin (TBIL) ≤ 1.5 × ULN; International Normalized Ratio (INR) ≤ 1.5 × ULN; Creatinine clearance ≥ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula); Left ventricular ejection fraction (LVEF) ≥ 50%; QTcF interval ≤ 480 ms.\n* Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and must be willing to use highly effective contraception during the study and for 180 days after the last dose.\n* Male participants with female partners of childbearing potential must be surgically sterile or willing to use highly effective contraception during the study and for 180 days after the last dose.\n* Able to understand and comply with study visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Prior systemic anti-tumor therapy for urothelial carcinoma, including radiotherapy, chemotherapy, targeted therapy, or biological therapy (except for intravesical instillation therapy).\n* Prior treatment with PD-1\u002FPD-L1 inhibitors or antibody-drug conjugates (ADCs).\n* Active malignancies other than urothelial carcinoma within 3 years prior to the first dose, except for curatively treated malignancies (e.g., basal or squamous cell skin cancer, localized low-risk prostate cancer, papillary thyroid cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast).\n* Active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to the first dose; or received high-dose steroids (\\>10 mg\u002Fday prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose. (Physiological replacement therapies are permitted).\n* Severe thromboembolic events or severe cardiovascular\u002Fcerebrovascular diseases within 1 year prior to the first dose, including but not limited to myocardial infarction, unstable angina, pulmonary embolism, cerebral hemorrhage, cerebral infarction, and deep vein thrombosis.\n* Major surgical procedure within 28 days prior to the first dose; or cystoscopy\u002Fureteroscopy biopsy or intravesical therapy within 7 days prior to the first dose.\n* Peripheral neuropathy ≥ Grade 2.\n* Severe dry eye syndrome, active keratitis, corneal ulcers, or conditions assessed by the investigator as increasing the risk of corneal disease and unsuitable for participation.\n* Active infections, including: Positive HBsAg with HBV-DNA copy number ≥ 500 IU\u002FmL; Positive HCV antibody with positive HCV-RNA; Positive HIV antibody; Active tuberculosis infection; Other active infections requiring systemic therapy within 7 days prior to the first dose.\n* Other severe or uncontrolled diseases, including but not limited to: Severe respiratory diseases (e.g., moderate-to-severe interstitial or obstructive pulmonary disease, severe asthma); New York Heart Association (NYHA) Class III or IV heart failure; HbA1c ≥ 8% (except for participants whose fasting blood glucose is stably controlled at ≤ 10 mmol\u002FL with medication); Poorly controlled hypertension (systolic BP ≥ 160 mmHg and\u002For diastolic BP ≥ 100 mmHg); Large pleural effusion or ascites requiring symptomatic treatment within 14 days prior to the first dose.\n* Receipt of live vaccines within 28 days prior to the first dose or plans to receive live vaccines during the study.\n* Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation.\n* Use of strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose.\n* Known severe hypersensitivity or intolerance to the study drugs or any of their excipients.\n* Substance abuse or psychiatric disorders that may interfere with study compliance.\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for the study.",{"count":428,"type":20},58,[134],"The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin. This regimen is evaluated as a neoadjuvant treatment for patients with locally advanced or high-risk muscle-invasive bladder cancer. Participants will be randomly assigned in a 1:1 ratio to one of two cohorts. Cohort A will receive Enfortumab Vedotin and Toripalimab for 3 treatment cycles. Cohort B will receive Gemcitabine and Cisplatin for 3 treatment cycles. Following the neoadjuvant treatment phase, patients will undergo radical cystectomy and pelvic lymph node dissection. The primary endpoint of the study is the 1-year Event-Free Survival (EFS) rate. Secondary endpoints include pathological downstaging rate (pDR), pathological complete response (pCR), Disease-Free Survival (DFS), Overall Survival (OS), and the assessment of adverse events. Additionally, the study will evaluate the relationship between treatment efficacy and the expression of PD-L1 and Nectin-4 in tumor tissues.",[432],"Muscle-Invasive Bladder Cancer (MIBC)",[434,435,436,437,438,439,440],"MIBC","Neoadjuvant Therapy","Enfortumab Vedotin","Toripalimab","Antibody-Drug Conjugates","Nectin-4","Urothelial Carcinoma",{"date":442,"type":35},"2026-06-15",{"date":444,"type":35},"2025-04-15",{"date":446,"type":20},"2028-12",{"name":41,"class":42},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":16,"minAge":455,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":43},"100585048","comparison-of-mbr--suture-tape-and-mbr-for-clai--a-prospective-cohort-study-100585048","NCT06897293","Comparison of MBR + Suture Tape and MBR for CLAI : A Prospective Cohort Study","Comparison of Modified Broström Repair + Suture Tape and Modified Broström Repair for Chronic Lateral Ankle Instability : A Prospective Cohort Study","Inclusion Criteria:\n\n* Clinical diagnosis of lateral ankle instability\n* Beighton score ≥4\n* Age with 18 to 60 years\n\nExclusion Criteria:\n\n* Patients with an acute or subacute ankle injury\n* Injury of the deltoid ligament\n* Alignment of lower extremity greater than 5 degrees\n* Fractures of the lower extremity\n* Stage III or IV osteoarthritis\n* Patients who refused to participate in the study","15 Years","55 Years",{"count":458,"type":20},86,"GJL is a risk factor for postoperative recurrent instability following an MBR for CLAI. Additional suture tape augmentation has been suggested to provide more strength and stability. However, the outcomes of the MBP with suture tape augmentation were unknown, which requires further exploration.",[461,462],"Ankle Sprain","Hypermobility, Joint","2026-05-18",{"date":465,"type":35},"2026-05-20",{"date":467,"type":35},"2021-06-01",{"date":469,"type":20},"2026-06-01",{"name":41,"class":42},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":130,"minAge":374,"maxAge":280,"enrollmentInfo":479,"targetDuration":4,"studyType":55,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100638840","early-prevention-and-precision-management-of-female-fertility-decline-100638840","NCT07581444","Early Prevention and Precision Management of Female Fertility Decline","Development and Evaluation of a Precision Prevention Strategy for Early Female Fertility Decline Based on OvaRePred-Plus: A Multicenter Cluster Randomized Controlled Trial","OvaRePred-Plus","Inclusion Criteria:\n\n* Women aged 20-40 years\n* Diagnosed with infertility or planning assisted reproductive treatment\n* Regular menstrual cycles (21-35 days)\n* Willing to participate in a 12-week lifestyle intervention program\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Known chromosomal abnormalities or genetic disorders affecting fertility\n* History of ovarian surgery or severe ovarian damage\n* Diagnosed endocrine disorders affecting reproduction (e.g., uncontrolled thyroid disease, hyperprolactinemia)\n* Severe systemic diseases (e.g., cardiovascular, hepatic, renal diseases)\n* Current pregnancy or breastfeeding\n* Use of hormonal medications or supplements affecting ovarian function within the past 3 months\n* Participation in another clinical trial within the past 3 months",{"count":480,"type":20},384,[57],"Female fertility decline has become an important public health issue in China, with a substantial proportion of women of reproductive age experiencing reduced ovarian reserve. However, effective tools for early identification and large-scale prevention of fertility impairment in the general population are still lacking.\n\nThis study aims to develop and evaluate a precision prevention strategy for early female fertility decline based on the OvaRePred-Plus model, which integrates ovarian reserve markers, lifestyle factors, and reproductive health indicators. A multicenter, cluster randomized controlled trial will be conducted across six medical centers in China, enrolling women aged 20-40 years identified as having early signs of fertility decline.\n\nParticipants will be allocated to either an intervention group receiving a comprehensive health management program (including dietary optimization, nutritional supplementation, physical activity, and sleep improvement) or a control group receiving routine clinical care. The intervention will last for 12 weeks.\n\nThe primary outcome is the change in fertility score assessed by the OvaRePred-Plus model. Secondary outcomes include changes in ovarian reserve markers (e.g., AMH), menstrual status, ultrasound parameters, and reproductive outcomes.\n\nThis study is expected to provide evidence for a scalable and cost-effective strategy for early prevention and management of female fertility decline.",[484,485,486,487],"Female Fertility Decline","Diminished Ovarian Reserve","Reproductive Health","Infertility Prevention","2026-05-06",{"date":490,"type":35},"2026-05-12",{"date":492,"type":20},"2026-06",{"date":494,"type":20},"2026-12",{"name":41,"class":42},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":202,"sex":16,"minAge":503,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":55,"phases":507,"briefSummary":508,"conditions":509,"keywords":514,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":43},"100633879","probiotic-intervention-on-the-development-of-allergic-diseases-in-infants-exposed-to-antibiotics-early-in-life-100633879","NCT07532421","Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","A Study on the Impact of Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","Inclusion Criteria:\n\n* Gestational age from 37 weeks to less than 41 weeks;\n* Birth weight between the 10th and 90th percentiles for gestational age;\n* Breastfed (exclusively breastfed after achieving stable feeding volume, with willingness to maintain exclusive breastfeeding for at least 3 months);\n* Postnatal age within 35 days; Consent to participate in this study.\n\nExclusion Criteria:\n\n* Postnatal Apgar score \\\u003C7;\n* Presence of severe congenital malformations or inherited metabolic diseases;\n* Use of probiotics by the infant or the mother within 2 weeks before enrollment.","1 Day","35 Days",{"count":506,"type":20},400,[57],"Early antibiotic exposure is an important environmental factor that disrupts the establishment of the infant gut microbiota and leads to microbial dysbiosis. Accumulating epidemiological evidence indicates that exposure to antibiotics early in life (including both prenatal and postnatal periods) is significantly associated with an increased risk of allergic diseases in childhood. As live microorganisms, probiotics hold potential as a preventive strategy against allergies due to their ability to stabilize the intestinal barrier and regulate immune balance (e.g., promoting Th1\u002FTh2 balance, inducing regulatory T cells, and increasing sIgA secretion). However, current studies have mostly focused on general or high-risk infant populations. For the specific high-risk subgroup that has already been exposed to antibiotics early in life, high-quality randomized controlled trial evidence is still lacking regarding whether probiotic intervention can effectively reduce the incidence of allergies and whether it exerts its effects by reshaping the gut microbiota and metabolites disrupted by antibiotics.\n\nThis study focuses on breastfed infants who received antibiotics during the early postnatal period (within 30 days after birth) and aims to investigate the effect of a probiotic mixture containing Bifidobacterium longum subsp. infantis R0033, Lactobacillus helveticus R0052, and Bifidobacterium bifidum R0071 on the development of allergic diseases after antibiotic exposure.",[510,511,512,513],"Antibiotic","Allergic Diseases","Infants","Probiotic",[515,516,517,518],"probiotics","infants","early postnatal antibiotic exposure","allergic diseases",{"date":520,"type":35},"2026-05-11",{"date":522,"type":20},"2026-04-17",{"date":524,"type":20},"2027-10-31",{"name":41,"class":42},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":16,"minAge":532,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":43},"100589955","prospective-cohort-study-on-fuzheng-yangxin-prescription-for-rapid-rehabilitation-of-patients-with-qi-yin-deficiency-syndrome-after-coronary-artery-bypass-grafting-100589955","NCT06961136","Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting","Inclusion Criteria:\n\n* Patients who received coronary artery bypass surgery with syndrome differentiation of Qi-Yin deficiency after operation\n\nExclusion Criteria:\n\n* ① Patients allergic to Fuzheng Yangxin Fang granules\n\n  * Patients with postoperative cold and fever ③ Patients with severe postoperative hepatic and renal insufficiency ④ Other circumstances: Concurrent valvular surgery or other cardiac surgery, end-stage malignant tumor, uncontrolled infection, bleeding, progressive degenerative systemic disease, severe brain injury, multiple organ failure, other vital organ dysfunction such as severe liver impairment, severe heart failure or cardiogenic shock, inability to tolerate surgery, etc.","25 Years","85 Years",{"count":325,"type":20},"Data from the Global Burden of Disease Study 2021, recently published in the Lancet, show that ischaemic heart disease remains the first most common cause of death worldwide. Ischemic heart disease mainly refers to coronary artery stenosis or obstruction caused by coronary artery atherosclerosis leading to myocardial ischemia heart disease, called coronary heart disease. \"China Cardiovascular Health and Disease Report 2022\" mentioned that coronary heart disease is an important cardiovascular disease affecting the health of Chinese residents, and its prevalence and mortality are on the rise. Coronary artery bypass grafting (CABG) and interventional therapy (PCI) are commonly used in the treatment of coronary heart disease. CABG surgery can significantly reduce the recurrence of angina pectoris, the incidence of acute myocardial infarction and improve the survival rate of patients, the patency rate of 5 years after mammary arterial bridge can reach more than 90%. Current guidelines and various RCT studies have shown that CABG is the gold standard for revascularization in patients with complex coronary artery disease. With the increasing aging of Chinese population, there are more and more cases of complex coronary artery diseases, and CABG, as the first choice for complex coronary artery diseases, will be more and more widely used in the foreseeable future. At present, the number of coronary artery bypass surgery is on the rise, about 50,000 cases per year. Traditional Chinese medicine can play a role in preventing complications, improving the quality of life and long-term curative effect of patients after CABG. It is particularly important to actively seek the treatment of integrated Chinese and Western medicine for patients after CABG. This study aims to explore the effectiveness and safety of Fuzheng Yangxin prescription in the treatment of Qi-Yin deficiency after CABG by means of a prospective cohort study, so as to determine the efficacy of Fuzheng Yangxin prescription on the recovery after CABG. To formulate a routine program of Chinese and Western combined therapy for postoperative rehabilitation of cardiac surgery, and actively promote the technology and program, promote the transformation of intellectual property rights, etc., and contribute to the formulation of relevant guidelines.",[537],"Coronary Artery Bypass",[537,539],"Chinese herbal medicine",{"date":541,"type":35},"2026-05-08",{"date":543,"type":35},"2025-05-10",{"date":190,"type":20},{"name":41,"class":42},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":254,"enrollmentInfo":553,"targetDuration":4,"studyType":55,"phases":555,"briefSummary":556,"conditions":557,"keywords":563,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":575},"100635403","nk-cell-therapy-for-malignant-solid-brain-tumors-100635403","NCT07552233","NK Cell Therapy for Malignant Solid Brain Tumors","NK Cell Therapy for the Treatment of Malignant Solid Brain Tumors","Inclusion Criteria:\n\n1. Male or female, age 18-70 years old (both ends included)\n2. At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment\n3. Karnofsky Performance Status (KPS) ≥ 60%\n4. Life expectancy \\> 4 weeks, and must be able to undergo an MRI with contrast\n5. Patients who completed radiotherapy or systemic therapies (including temozolomide\u002Fbevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0)\n6. Dexamethasone dose ≤ 4 mg\u002Fday or equivalent corticosteroid dose, or no dexamethasone administered\n7. Must have adequate organ and marrow function as defined below:\n\n   * White blood cell count (WBC) ≥ 3 x 10\\^9\u002FL\n   * Absolute neutrophil count (ANC) \\> 1 x 10\\^9\u002FL\n   * Hemoglobin (Hb) ≥ 90 g\u002FL\n   * Platelet (PLT) ≥ 80×10\\^9\u002FL\n   * Albumin transaminase (ALT) \\& albumin transaminase (AST) \\\u003C 1.5 × institutional upper limit of normal (ULN)\n   * Serum creatinine (Cr) \\\u003C 1.5 x institutional ULN\n   * Total bilirubin \\\u003C 1.5 x institutional ULN\n   * PT \\& PTT ≤ 1.25 x institutional ULN\n8. No obvious hereditary diseases\n9. Normal cardiac function with left ventricular ejection fraction \\>55%\n10. No bleeding and coagulation disorders\n11. Absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to NK cell infusion and\u002For there aren't any indications of meningitis\n12. Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n13. Signed, written informed consent\n\nExclusion Criteria:\n\n1. Active hepatitis B or C virus, HIV infection, or other untreated active infection\n2. Pregnant and lactating women\n3. Participants with organ failure\n4. Participants with a chronic disease requiring immunologic or hormonal therapy\n5. Participants with an allergy to immunotherapy and related cells\n6. Participants with uncontrolled intercurrent illness\n7. Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n8. Participants with a history of organ transplantation or who are awaiting organ transplantation",{"count":554,"type":20},27,[57],"This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as measured by progression-free survival (PFS), overall survival (OS), objective response rate (ORR) per RANO criteria, and evaluation of the immunological effects of NK cell infusion in the tumor microenvironment and peripheral blood.",[558,559,560,561,562],"Malignant Solid Brain Tumors","Glioblastoma (GBM)","Glioblastoma Multiforme (GBM)","Brain Metastasis","Malignant Meningioma",[558,564,565,566],"Immunotherapy","Natural Killer Cell","NK Cell","2026-04-20",{"date":569,"type":35},"2026-04-27",{"date":571,"type":20},"2026-04",{"date":573,"type":20},"2030-12-31",{"name":41,"class":42},4,{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":583,"enrollmentInfo":584,"targetDuration":4,"studyType":55,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":596,"locationsCount":43},"100510264","effects-of-preoperative-rehabilitation-on-tendon-healing-bone-mineral-density-and-cartilage-after-aclr-and-patellar-dislocation-100510264","NCT05924178","Effects of Preoperative Rehabilitation on Tendon Healing, Bone Mineral Density, and Cartilage After ACLR and Patellar Dislocation","A Study on the Effect of Exercise Rehabilitation on Bone Mineral Density, Reconstruction Ligament Tendon Bone Healing and Cartilage After ACL Rupture and Patellar Dislocation","Inclusion Criteria:\n\n1. Age 18\\~40 years old, diagnosed ACL rupture or Patellar Dislocation by MRI;\n2. The first unilateral ligamenta reconstruction at our hospital;\n\nExclusion Criteria:\n\n1. Be older than 40 years, or less than 18 years old\n2. Severe injury to other knee ligaments\n3. History of knee trauma","45 Years",{"count":585,"type":20},60,[57],"To explore the effect of preoperative exercise rehabilitation on bone mineral density, tendon bone healing, change of cartilage, and gait feature in patients with anterior cruciate ligament rupture.",[589],"Anterior Cruciate Ligament Rupture","2026-04-12",{"date":592,"type":35},"2026-04-15",{"date":594,"type":35},"2023-07-10",{"date":469,"type":20},{"name":41,"class":42},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":130,"minAge":17,"maxAge":4,"enrollmentInfo":603,"targetDuration":455,"studyType":22,"phases":4,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":43},"100633880","a-bidirectional-cohort-study-on-prophylactic-resection-surgery-in-populations-at-moderate-to-high-risk-for-hereditary-ovarian-cancer-100633880","NCT07532434","A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer","Inclusion Criteria:\n\n* Gender: Female. Age: 18 years or older at the time of enrollment.Genetic Risk: Documented carriers of pathogenic or likely pathogenic germline mutations in high-risk ovarian cancer susceptibility genes (including BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2). Data Availability: Willing to provide informed consent and allow access to clinical records, genetic testing reports, and follow-up data (bidirectional cohort). Psychosocial Status: Ability to complete quality of life and psychological assessment scales (e.g., GCS, SF-36, FSFI).\n\nExclusion Criteria:\n\n* Prior Malignancy: History of ovarian, fallopian tube, or primary peritoneal cancer prior to the baseline intervention. Synchronous Malignancy: Diagnosis of any other advanced-stage malignancy. Inability to Follow-up: Significant psychological, social, or geographical factors that would prevent regular long-term follow-up (3 years). Previous Extensive Pelvic Surgery: History of extensive pelvic surgery that precludes the feasibility of laparoscopic prophylactic salpingectomy or oophorectomy.",{"count":604,"type":20},480,"The goal of this multi-center observational study is to learn about the effectiveness and safety of different prophylactic (preventive) surgical options in women at moderate-to-high genetic risk for hereditary ovarian cancer (HOC).\n\nThe main questions it aims to answer are:\n\nDoes individualized prophylactic surgery (such as removing fallopian tubes now and delaying ovary removal) effectively reduce the risk of developing ovarian cancer compared to standard care or close monitoring?\n\nHow do these different surgical interventions affect a woman's ovarian function and quality of life?\n\nWhat Participants Will Do:\n\nParticipants who are healthy carriers of specific genetic mutations (such as BRCA1\u002F2, RAD51C\u002FD, etc.) will be followed in a bidirectional cohort. Depending on the medical care and surgical path they choose with their doctors (Standard RRSO, Delayed Oophorectomy, or Close Monitoring), researchers will collect their clinical data, surgical pathology results, and follow-up information regarding cancer incidence and quality of life for 3 years.",[65,63],[608,609,610,611,612],"Hereditary Ovarian Cancer (HOC)","BRCA1\u002F2 Mutation Carriers","Risk-Reducing Salpingo-Oophorectomy (RRSO)","Bidirectional Cohort Study","Risk-Reducing Salpingo-Oophorectomy（RRSO）","2026-04-08",{"date":592,"type":35},{"date":616,"type":35},"2025-09-30",{"date":618,"type":20},"2035-09-30",{"name":41,"class":42},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":583,"enrollmentInfo":626,"targetDuration":4,"studyType":55,"phases":628,"briefSummary":629,"conditions":630,"keywords":632,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":641},"100625525","effects-of-a-preoperative-cognitive-behavioral-intervention-on-kinesiophobia-and-function-in-anterior-cruciate-ligament-reconstruction-100625525","NCT07423767","Effects of a Preoperative Cognitive-Behavioral Intervention on Kinesiophobia and Function in Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n1. Patients aged 18 to 45 years with a diagnosis of anterior cruciate ligament (ACL) rupture.\n2. ACL rupture within 3 months prior to enrollment.\n3. First-time ACL rupture with a scheduled reconstruction surgery at this institution.\n4. The affected knee shows no significant redness, swelling, pain, or inflammation, with basic activities of daily living restored.\n5. No injury or only mild (grade I) injury to the posterior cruciate ligament, medial collateral ligament, or lateral collateral ligament.\n\nExclusion Criteria:\n\n1. Body mass index (BMI) less than 18.5 or greater than 35 kg\u002Fm².\n2. Age older than 45 years or younger than 18 years.\n3. ACL rupture with a duration exceeding 3 months.\n4. Concurrent severe injury (greater than grade I sprain) to the posterior cruciate ligament, medial collateral ligament, or lateral collateral ligament. (Note: Grade II indicates partial tear with ligament thickening, laxity, and partial fiber disruption; Grade III indicates complete rupture).\n5. Concurrent severe meniscal tear.\n6. History of prior knee surgery (e.g., meniscal repair, ligament reconstruction, joint replacement, arthroscopic debridement).\n7. Presence of other significant knee pathologies, such as: knee osteoarthritis, knee tumor, rheumatoid arthritis, tuberculosis, or active infectious\u002Finflammatory diseases of the knee.\n8. Concurrent fracture, dislocation, or other osseous injuries involving the knee.\n9. Unwillingness to receive the treatment protocol of this study.",{"count":627,"type":20},44,[57],"This study aims to systematically elucidate the integrative effects of psychological rehabilitation on the \"brain-psychology-motor\" triad in patients with anterior cruciate ligament (ACL) rupture. We plan to recruit 44 patients (aged 18-45) diagnosed with ACL rupture and scheduled for reconstruction surgery at Peking University Third Hospital, who will be randomly assigned to two groups. Through synchronous acquisition of questionnaire scores, motor performance data (gait, jogging, postural stability), and central neural activity (EEG), this research seeks to establish a foundation for developing neuroscience evidence-based, precision rehabilitation strategies.",[631],"Anterior Cruciate Ligament (ACL) Tear",[633],"Anterior cruciate ligament; Cognitive-Behavioral Intervention",{"date":635,"type":35},"2026-04-13",{"date":637,"type":35},"2026-02-14",{"date":639,"type":20},"2027-08-01",{"name":41,"class":42},2,""]